In Brief: Genentech hGH patent suit
Executive Summary
Genentech hGH patent suit: D.C. federal appeals court grants interim stay of a lower court's preliminary injunction barring Novo from marketing its human growth hormone product Norditropin. The Dec. 17 court order is a reversal of its Aug. 1 order denying Novo's motion for a stay. Genentech says it still expects to have a full patent infringement trial for a permanent injunction ("The Pink Sheet" April 15, T&G-3)...